Labcorp Holdings
LH
311.97
+0.26
+0.08%
Labcorp Holdings
US · LH
#790 by market cap
Listed 1970
311.97
+0.26
+0.08%
Live - 5344 symbols - heartbeat 201s ago
· 2026-10-08 08:05
Pre-market
312.50
+0.17%
After-hours
311.97
0.00%
- Market cap
- 25.30B
- P/E (TTM)i
- 25.80
- P/Bi
- 2.94
- EPSi
- 10.46
- Div yieldi
- 0.92%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on LH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 103.19% -0.33pp
- Institutions
- 1,257 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund90.39%
Hedge Fund4.76%
Public Company3.59%
Government Pension Fund1.41%
Private Company1.11%
Sovereign Wealth Fund1.05%
Individual/Insider0.39%
Family Office/Trust0.35%
Insurance Company0.27%
Top holders as of 2026-06-30
BlackRock
8.11% · 6.57M sh
Vanguard Capital Management, LLC
7.18% · 5.82M sh
Victory Capital Management Inc.
5.96% · 4.84M sh
State Street Global Advisors
4.82% · 3.91M sh
Vanguard Portfolio Management, LLC
4.54% · 3.68M sh
Boston Partners Global Investors, Inc.
3.76% · 3.05M sh
Allspring Global Investments, LLC
2.76% · 2.24M sh
Geode Capital Management, LLC
2.70% · 2.19M sh
Select Equity Group, L.P.
2.44% · 1.98M sh
FMR
2.26% · 1.83M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Adam Schechter | Chairperson & CEO | 0.13% |
| Glenn Eisenberg | Chief Financial Officer | 0.05% |
| Brian Caveney | EVP, President of Early Development Research Laboratories & Chief Medical Officer | 0.05% |
| Lance Berberian | Executive VP and Chief Information & Technology Officer | 0.02% |
| Peter Neupert | Independent Director | 0.02% |
| Garheng Albert Kong | Lead Independent Director | 0.02% |
| Mark Schroeder | Executive VP, President of Diagnostics Laboratories & COO | 0.02% |
| Amy Summy | Chief Marketing Officer | 0.01% |
| Kerrii Anderson | Independent Director | 0.01% |
| Bryan Vaughn | Executive Vice President of Diagnostics | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Brian Caveney | EVP, President of Early Development Research Laboratories & Chief Medical Officer | Other Derivative Acquisition | +3,000 | -- |
| 2026-08-31 | Akinbolade Oyegunwa | Executive VP and Chief Information & Technology Officer | Other Derivative Acquisition | +750 | -- |
| 2026-08-31 | Jonathan Meltzer | Officer | Other Derivative Acquisition | +900 | -- |
| 2026-08-31 | Bryan Vaughn | Executive Vice President of Diagnostics | Other Derivative Acquisition | +1,500 | -- |
| 2026-08-16 | Kerrii Anderson | Independent Director | Automatic Disposition | -3,000 | $318.02 |
| 2026-08-10 | Adam Schechter | Chairperson & CEO | Automatic Disposition | -4,669 | $320.37 |
| 2026-08-03 | Amy Summy | Chief Marketing Officer | Open Market Disposition | -924 | $306.74 |
| 2026-08-02 | Peter Wilkinson | Chief Accounting Officer | Open Market Disposition | -82 | $309.22 |
| 2026-08-02 | Peter Wilkinson | Chief Accounting Officer | Derivative Exercise and Sale | -1,338 | $209.25–309.23 |
| 2026-07-01 | Kathryn Kyle | Executive VP, Chief Legal Officer and Corporate Secretary | Derivative Exercise and Sale | -165 | $283.88–286.19 |
| 2026-07-01 | Kathryn Kyle | Executive VP, Chief Legal Officer and Corporate Secretary | Intent to Sell (Form 144) | -92 | $286.19 |
| 2026-07-01 | Bryan Vaughn | Executive Vice President of Diagnostics | Derivative Exercise and Sale | -327 | $283.88–286.19 |
| 2026-07-01 | Bryan Vaughn | Executive Vice President of Diagnostics | Intent to Sell (Form 144) | -234 | $286.19 |
| 2026-06-30 | Sandra van der Vaart | Executive VP, Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | Intent to Sell (Form 144) | -7,138 | $280.48 |
| 2026-06-30 | Kathryn Kyle | Executive VP, Chief Legal Officer and Corporate Secretary | Derivative Exercise and Retained | +91 | -- |
| 2026-06-07 | Kathryn Kyle | Executive VP, Chief Legal Officer and Corporate Secretary | Automatic Disposition | -762 | $263.89 |
| 2026-05-10 | Adam Schechter | Chairperson & CEO | Automatic Disposition | -5,903 | $254.50 |
| 2026-05-05 | Sandra van der Vaart | Executive VP, Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | Intent to Sell (Form 144) | -6,238 | $256.76 |
| 2026-03-26 | Peter Wilkinson | Chief Accounting Officer | Automatic Disposition | -1,633 | $267.05 |
| 2026-03-26 | Jonathan Meltzer | Officer | Automatic Disposition | -839 | $267.05 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:05:17 · For reference only, not investment advice and not tailored to your situation.